Navigation Links
AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments

LONDON and GLOSTRUP, Denmark, Jan. 18 /PRNewswire-FirstCall/ -- AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development.

(Logo: )

(Logo: )

Under the agreement, the companies will work together to develop diagnostic tests to help physicians determine the most appropriate cancer treatment for patients. The financial terms of the deal were not disclosed.

The collaboration will leverage Dako's position as a leader in cancer diagnostics and a strong partner in the development of diagnostic tests used in conjunction with drug therapies. AstraZeneca will bring its extensive experience in the development and commercialization of vital oncology products worldwide.

"We believe it is important for pharmaceutical and diagnostic companies to combine their expertise in a strong collaborative approach to enable the development of diagnostic tests for use with drug therapies. Targeted treatment with personalized medicine is the future, and the outcome of this collaboration will be beneficial not only for cancer patients, but is also a significant contributive factor in cutting health care costs," says Lars Holmkvist, CEO of Dako Denmark A/S.

Alan Barge, Head of Oncology Development at AstraZeneca said: "This agreement, under the umbrella of AstraZeneca's Personalised Healthcare strategy, will enable us to develop novel, reimbursable products that can improve patients' lives. The alliance heralds the intentions of both companies to work closely together to develop new drugs linked to diagnostic tests that predict which patients are most likely to respond to treatment, ensuring that we are giving the right treatment, to the right patient, the first time."

Ruth March, Personalised Healthcare Leader at AstraZeneca, said: "This agreement is the first in a series of strategic alliances with diagnostic companies that will enable AstraZeneca to achieve our Personalised Healthcare aims and better serve patient health." 

For AstraZeneca, today's announcement marks the continuation of their commitment to Personalised Healthcare as demonstrated by the launch of IRESSA in the EU for patients with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase).

The agreement advances Dako's ongoing strategy to collaborate with strong partners in the pharmaceutical sector to enhance the offering of Dako's companion diagnostic assays.

About Dako

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and operating in more than 70 countries, Dako covers essentially all of the global anatomic pathology markets. Dako is owned by a private equity fund, EQT.

About AstraZeneca

AstraZeneca (NYSE: AZN)  is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world´s leading pharmaceutical companies with healthcare sales of US$31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit:

SOURCE AstraZeneca

AP Archive:


SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
2. Novexel to be Acquired by AstraZeneca
3. AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
4. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
5. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
6. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
7. Jubilant Enters Research Collaboration With AstraZeneca
8. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
9. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
10. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
11. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... ... 25, 2015 , ... TyloHelo Inc , North America’s ... Sauna accessories help improve the bather experience in the sauna, and the accessories ... the purist looking for simplicity in design to accessories that encourage a greater ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
Breaking Medicine News(10 mins):